Christine Rousseau

Dr. Christine Rousseau became Chief Business Development Officer on December 1, 2020. She brings over 20 years of international experience as a life sciences executive supporting the development of diagnostics, devices and vaccines. She has skills in strategy development, partnership engagement, clinical/regulatory affairs (Global Health, Infectious Disease, Cancer) and operational management.

In her role as a Vice President of Corporate Development at Chembio Diagnostics Systems, Inc. and as Senior Program Officer at the Bill & Melinda Gates foundation, she established partnerships between major biopharmaceutical, diagnostic industry, academia and global organizations including Takeda, Mylan, Roche, UNICEF, UNITAID, the Global Fund and many others. Most recently, she led and closed deals raising $8.5M/year for Chembio Diagnostics Systems, Inc. At the Bill & Melinda Gates foundation, she directed over $250M USD in assets for the development of molecular, cellular and serology diagnostic technologies. To enable such technology development, her work included the creation of an innovation hub to support laboratory systems globally and an African research organization to support clinical studies necessary for regulatory submission. She has played several leadership roles on cross-functional teams covering corporate strategy, acquisition prospecting, deal negotiations and financial investments, i.e. grants, equity, loans, strategic partnerships and license agreements.

Rousseau has been recognized consistently by peers for integrity, strategic acumen, leadership and scientific expertise. She received her B.S. in Molecular Genetics from Ohio State University (Columbus, Ohio), her Ph.D. in Molecular and Cell Biology from the University of California (Berkeley, Calif.), and an M.S. in Epidemiology from the University of Washington (Seattle).